Photocure

OL:PHO Norway Drug Manufacturers - Specialty & Generic
Market Cap
$153.19 Million
Nkr1.75 Billion NOK
Market Cap Rank
#17653 Global
#63 in Norway
Share Price
Nkr65.60
Change (1 day)
-2.53%
52-Week Range
Nkr48.40 - Nkr79.00
All Time High
Nkr150.90
Categories
Companies in Norway Drug Manufacturers - Specialty & Generic
About

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced ce… Read more

Photocure (PHO) - Net Assets

Latest net assets as of September 2025: Nkr486.60 Million NOK

Based on the latest financial reports, Photocure (PHO) has net assets worth Nkr486.60 Million NOK as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr696.70 Million) and total liabilities (Nkr210.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets Nkr486.60 Million
% of Total Assets 69.84%
Annual Growth Rate 1.42%
5-Year Change -1.26%
10-Year Change 138.84%
Growth Volatility 122.22

Photocure - Net Assets Trend (2000–2024)

This chart illustrates how Photocure's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Photocure (2000–2024)

The table below shows the annual net assets of Photocure from 2000 to 2024.

Year Net Assets Change
2024-12-31 Nkr501.72 Million +3.91%
2023-12-31 Nkr482.85 Million +4.35%
2022-12-31 Nkr462.73 Million -7.94%
2021-12-31 Nkr502.63 Million -1.08%
2020-12-31 Nkr508.13 Million +143.60%
2019-12-31 Nkr208.59 Million +18.29%
2018-12-31 Nkr176.34 Million -19.14%
2017-12-31 Nkr218.08 Million -13.44%
2016-12-31 Nkr251.94 Million +19.94%
2015-12-31 Nkr210.06 Million -12.50%
2014-12-31 Nkr240.06 Million -10.80%
2013-12-31 Nkr269.12 Million -29.23%
2012-12-31 Nkr380.27 Million -13.45%
2011-12-31 Nkr439.34 Million -4.25%
2010-12-31 Nkr458.85 Million +10.36%
2009-12-31 Nkr415.78 Million +108.21%
2008-12-31 Nkr199.69 Million -23.19%
2007-12-31 Nkr259.99 Million -20.48%
2006-12-31 Nkr326.94 Million +574.58%
2005-12-31 Nkr48.47 Million -43.36%
2004-12-31 Nkr85.57 Million -35.13%
2003-12-31 Nkr131.90 Million -21.02%
2002-12-31 Nkr167.00 Million -35.62%
2001-12-31 Nkr259.40 Million -27.41%
2000-12-31 Nkr357.36 Million --

Equity Component Analysis

This analysis shows how different components contribute to Photocure's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 627800000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings Nkr6.28 Million 1.25%
Common Stock Nkr13.56 Million 2.70%
Other Components Nkr481.88 Million 96.05%
Total Equity Nkr501.72 Million 100.00%

Photocure Competitors by Market Cap

The table below lists competitors of Photocure ranked by their market capitalization.

Company Market Cap
Fabasoft AG
PINK:FBSFF
 		$114.81 Million
SCI Pharmtech Inc
TW:4119
 		$114.82 Million
MultiPlan Corporation
NYSE:MPLN
 		$114.82 Million
Saha-Union Public Company Limited
BK:SUC
 		$114.86 Million
Kalyani Steels Limited
NSE:KSL
 		$114.76 Million
Sitka Gold Corp
OTCQB:SITKF
 		$114.76 Million
IAR Systems Group AB (publ)
PINK:IARGF
 		$114.75 Million
079900
KO:079900
 		$114.70 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Photocure's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 482,848,000 to 501,716,000, a change of 18,868,000 (3.9%).
  • Net loss of 3,339,000 reduced equity.
  • Other factors increased equity by 22,207,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Nkr-3.34 Million -0.67%
Other Changes Nkr22.21 Million +4.43%
Total Change Nkr- 3.91%

Book Value vs Market Value Analysis

This analysis compares Photocure's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.54x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 6.84x to 3.54x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2002-12-31 Nkr9.59 Nkr65.60 x
2003-12-31 Nkr7.48 Nkr65.60 x
2004-12-31 Nkr4.86 Nkr65.60 x
2005-12-31 Nkr2.75 Nkr65.60 x
2006-12-31 Nkr15.30 Nkr65.60 x
2007-12-31 Nkr11.70 Nkr65.60 x
2008-12-31 Nkr9.04 Nkr65.60 x
2009-12-31 Nkr18.82 Nkr65.60 x
2010-12-31 Nkr20.99 Nkr65.60 x
2011-12-31 Nkr20.39 Nkr65.60 x
2012-12-31 Nkr17.81 Nkr65.60 x
2013-12-31 Nkr12.63 Nkr65.60 x
2014-12-31 Nkr11.25 Nkr65.60 x
2015-12-31 Nkr9.78 Nkr65.60 x
2016-12-31 Nkr11.70 Nkr65.60 x
2017-12-31 Nkr10.12 Nkr65.60 x
2018-12-31 Nkr8.15 Nkr65.60 x
2019-12-31 Nkr9.55 Nkr65.60 x
2020-12-31 Nkr20.49 Nkr65.60 x
2021-12-31 Nkr18.54 Nkr65.60 x
2022-12-31 Nkr17.04 Nkr65.60 x
2023-12-31 Nkr17.81 Nkr65.60 x
2024-12-31 Nkr18.51 Nkr65.60 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Photocure utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -0.67%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -0.64%
  • • Asset Turnover: 0.71x
  • • Equity Multiplier: 1.47x
  • Recent ROE (-0.67%) is above the historical average (-11.98%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2002 -57.49% -380.62% 0.08x 1.79x Nkr-112.70 Million
2003 -32.65% -77.54% 0.24x 1.78x Nkr-55.87 Million
2004 -52.73% -57.87% 0.45x 2.03x Nkr-53.57 Million
2005 -78.84% -71.23% 0.51x 2.18x Nkr-43.06 Million
2006 26.02% 40.45% 0.56x 1.15x Nkr52.39 Million
2007 -28.94% -75.72% 0.33x 1.16x Nkr-100.87 Million
2008 -32.24% -62.98% 0.43x 1.19x Nkr-84.35 Million
2009 75.13% 645.04% 0.11x 1.10x Nkr270.80 Million
2010 3.94% 10.20% 0.35x 1.12x Nkr-27.79 Million
2011 -1.71% -6.50% 0.23x 1.16x Nkr-51.45 Million
2012 -12.60% -35.79% 0.31x 1.14x Nkr-85.93 Million
2013 -21.90% -70.50% 0.28x 1.12x Nkr-85.86 Million
2014 -10.29% -19.15% 0.48x 1.13x Nkr-48.71 Million
2015 -17.22% -26.85% 0.54x 1.18x Nkr-57.18 Million
2016 14.01% 24.58% 0.50x 1.13x Nkr10.11 Million
2017 -15.91% -22.99% 0.57x 1.21x Nkr-56.51 Million
2018 -20.82% -20.22% 0.79x 1.31x Nkr-54.34 Million
2019 15.26% 11.31% 1.09x 1.23x Nkr10.97 Million
2020 -4.41% -8.73% 0.33x 1.53x Nkr-73.22 Million
2021 -6.15% -8.57% 0.46x 1.57x Nkr-81.16 Million
2022 -15.53% -18.28% 0.55x 1.55x Nkr-118.13 Million
2023 0.20% 0.20% 0.70x 1.47x Nkr-47.31 Million
2024 -0.67% -0.64% 0.71x 1.47x Nkr-53.51 Million

Industry Comparison

This section compares Photocure's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $309,529,000
  • Average return on equity (ROE) among peers: 20.27%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Photocure (PHO) Nkr486.60 Million -57.49% 0.43x $114.80 Million
Vistin Pharma ASA (VISTN) $309.53 Million 20.27% 0.24x $40.47 Million